Trial Profile
A Prospective, multicenter study to evaluate aflibercept therapy and its response to pigment epithelial detachments in patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 07 Apr 2017 New trial record